Intriguingly, the adverse prognosis in the CHIP(−)/RIPK3(+) group may imply that due to the absence of CHIP, RIPK3 was able to remain intact and activate the necroptosis pathway, which in turn promoted tumor progression; this is in line with the adverse prognosis associated with RIPK3 expression observed in our study. This evidence concerns the gene RIPK3 and neoplasm.